A market growing at ~31% a year.
Full-Spectrum cannabis oil carries materially higher therapeutic value and price than isolates or raw flower. Demand is expanding rapidly — particularly across regulated European healthcare markets.
Germany leads. Portugal supplies.
Germany — the engine
The largest medical-cannabis market in Europe, reaching over €670M in 2025 with projections exceeding €1bn by 2028 and €3.5bn by 2030. Imports reached approximately 201 tonnes in 2025 — nearly triple the 72 tonnes of 2024, with Portugal supplying around 29% of that volume.
United Kingdom
The second-largest European market, valued at over €300M in 2025, with roughly 80,000 patients by year-end and demand expected to exceed 100,000 in 2026. Around 90% of medical-cannabis flower prescribed in the UK is imported — mainly from Canada, Portugal and Spain.
Italy
Consistently among Europe's largest markets alongside Germany, Spain and Portugal, with limited domestic production and a heavy reliance on imports to meet demand.
Portugal — the gateway
Portugal is the second-largest exporter worldwide behind only Canada. Exports grew from 709 kg in 2019 to 32,558 kg in 2024 — a rise of 172% in 2024 alone. INFARMED oversight aligned to GACP and GMP export standards.
Premium product, value-added — not the commodity trap.
The project targets premium Full-Spectrum oil for export across high-demand markets — Germany, the UK, Switzerland and beyond. It is deliberately positioned away from the commodity flower segment, where prices have been falling internationally.
Sources: Prohibition Partners, BfArM, INFARMED, GrowerIQ and industry market reports (2025–2026). Figures are indicative and compiled for context.